Latest Compliance News

Resource Mining Corporation Limited (RMI) has responded to a sharp surge in its share price and trading volume, denying any undisclosed material information while pointing to ongoing copper-gold exploration activities at its Mpanda Project in Tanzania.

Catalyst Metals has received the final environmental approval to begin mining at its Trident Gold Project, marking a key step in its plan to double production at the Plutonic Gold Belt.

Heavy Minerals Limited attributes its recent share price jump to media coverage about its upcoming Port Gregory Pre-Feasibility Study and confirms compliance with ASX disclosure rules.

Sigma Healthcare has released its standalone annual and sustainability reports for the year ending January 2025, marking the final disclosures before its merger with Chemist Warehouse Group in February 2025.

Southern Cross Gold has successfully closed the second tranche of its C$143 million private placement, securing nearly C$30 million to fund critical milestones at its Sunday Creek Gold-Antimony Project in Australia.

Genetic Technologies Limited has announced significant leadership changes, appointing Michael Walker as Executive Chairman and Managing Director, alongside new executive and board members.

Celsius Resources Limited has launched an offer of up to 423.95 million new options to key placement participants, including Silvercorp Metals and its lead manager, aiming to support ongoing project funding without immediate capital inflow.

Future Metals NL has announced a partially underwritten entitlement offer aiming to raise approximately AUD 2.64 million to support development of its Eileen Bore Project and working capital needs. The offer opens to eligible shareholders on 15 May 2025 and closes on 30 May 2025.

EDU Holdings Limited plans to voluntarily delist from the ASX, citing low share liquidity and regulatory uncertainty in the international student market. The company proposes a substantial buy-back offer to provide shareholders with an exit opportunity ahead of delisting.

Emu NL has raised $300,000 through a placement of 17.6 million shares priced at 1.7 cents each, aiming to fund its exploration projects and support working capital needs.

Mayne Pharma has voluntarily withdrawn a speaker presentation for its contraceptive NEXTSTELLIS® following an FDA Untitled Letter concerning promotional claims. The company confirms this does not impact sales or its planned merger with Cosette.

Mayne Pharma has addressed a sharp share price decline following the public release of an FDA Untitled Letter, confirming no undisclosed material information and reaffirming compliance with ASX rules.